Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 5/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.65 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.50 |
| ▸ | PREP | P48147 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.47 |
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4122759 | 0.96 | TMEM97 (0.60) | TMEM97SIGMAR1PREPNPC1RAB9A | |
| SCHEMBL4033512 | 0.91 | TMEM97 (0.68) | TMEM97SIGMAR1FKBP1APREPNPC1 | |
| SCHEMBL5456476 | 0.91 | SIGMAR1 (0.63) | TMEM97SIGMAR1FKBP1APREPNPC1 | |
| SCHEMBL27924857 | 0.91 | TMEM97 (0.63) | TMEM97SIGMAR1FKBP1APREPNPC1 | |
| Water SCHEMBL27700641 | 0.90 | TMEM97 (0.67) | TMEM97SIGMAR1FKBP1APREPNPC1 | |
| SCHEMBL27924834 | 0.90 | TMEM97 (0.62) | TMEM97SIGMAR1FKBP1APREPNPC1 | |
| Water SCHEMBL27740102 | 0.89 | TMEM97 (0.66) | TMEM97SIGMAR1FKBP1APREPNPC1 | |
| SCHEMBL5466528 | 0.89 | TMEM97 (0.63) | TMEM97SIGMAR1FKBP1APREPNPC1 | |
| Hydrochloric Acid SCHEMBL30145608 | 0.87 | TMEM97 (0.64) | TMEM97SIGMAR1FKBP1APREPNPC1 | |
| SCHEMBL4123903 | 0.87 | TMEM97 (0.58) | TMEM97SIGMAR1PREPNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191420-A1 | Kinase inhibitors | DEVGEN NV | 2007-08-16 | — | — | US | disclosed |
| EP-1715862-A1 | KINASE INHIBITORS | Devgen NV (BE) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005082367-A1 | KINASE INHIBITORS | DEVGEN NV (BE) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191420-A1 | Kinase inhibitors | ROCK1, ROCK2, MAP3K20 | TMEM97 4472/4885SIGMAR1 4594/4885FKBP1A 2682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.